Current targets for anticancer drug discovery

Keyphrases

• Cancer Drug Discovery 100%
• Protein Kinase 50%
• Growth Factors 50%
• Telomerase 50%
• Angiogenesis Inhibition 50%
• Histone Deacetylase 1 (HDAC1) 50%
• Receptor-interacting Protein Kinase 1 (RIPK1) 25%
• Less Toxic 25%
• Malignancy 25%
• Recent Advances 25%
• Receptor Tyrosine Kinase 25%
• Vascular Endothelial Growth Factor 25%
• Apoptosis 25%
• Endothelial Cells 25%
• Drug Discovery 25%
• Blood Vessels 25%
• Molecular Targets 25%
• Matrix Metalloproteinases 25%
• Cell Cycle Regulators 25%
• Main Components 25%
• Growth Factor Receptor Tyrosine Kinase 25%
• Cell Adhesion Molecules 25%
• Tumor Angiogenesis 25%
• Platelet-derived Growth factor-BB (PDGF-BB) 25%
• Cyclin-dependent Kinase 25%
• Src Kinase 25%
• P53 Tumor Suppressor Gene 25%
• Cell Signaling Pathways 25%
• Fibroblast Growth Factor 1 (FGF1) 25%
• P21 Gene 25%
• Matrix Cell 25%
• Abl Kinase 25%
• Farnesyltransferase 25%
• Survivin Protein 25%
• Cellular Lifespan 25%
• Protein Farnesyltransferase 25%
• Anticancer Drug Design 25%
• Bcl-2 Oncoprotein 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticarcinogen 100%
• Drug Discovery 100%
• Malignant Neoplasm 40%
• Telomerase 40%
• Protein Tyrosine Kinase 40%
• Protein Kinases 40%
• Growth Factor 40%
• Histone Deacetylase 40%
• Neoplasm 20%
• Receptor 20%
• Cell Adhesion Molecule 20%
• Protein P53 20%
• Protein Bcl 2 20%
• Vasculotropin 20%
• Drug Development 20%
• Tumor Suppressor Protein 20%
• Matrix Metalloproteinase 20%
• Molecular Target 20%
• Cyclin Dependent Kinase 20%
• Protein Farnesyltransferase 20%
• Growth Factor Receptor 20%
• Platelet Derived Growth Factor 20%
• Fibroblast Growth Factor 20%
• Survivin 20%